ClinicalTrials.gg
RecruitingNCT07051083MICS-BCUpdated Jul 3, 2025

Bladder Cancer Staging and Prediction of New Adjuvant Chemotherapy Efficacy Based on Deep Learning and Transfer Learning in Ultrasound-Magnetic Resonance-Pathology Multimodal Multiscale

An observational study in Bladder Cancer, Staging and Deep Learning, sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2025-07-03.

Sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Observational

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
480
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Urinary Bladder Neoplasms by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University — 14 open to participants now, 14 under way, 1 of them phase 3. Urinary Bladder Neoplasms · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University.

Planned enrollment
6th of 13
480 · median 480
Started
2024
with 2 others
Observational
13 of 21
7 open now
Primary completion
2026-12
later than 8 of 13 live
Registered
13th of 21
by date

Among the 21 studies in Urinary Bladder Neoplasms by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, this one is the 6th largest by planned enrollment of the 13 observational ones that give a count, is one of 3 that started in 2024, is one of 13 observational ones, reaches primary completion later than 8 of the 13 other live ones, and was the 13th registered.

Urinary Bladder Neoplasms

1,803 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.

Browse Urinary Bladder Neoplasms studies →

Open to participants now

14 of the 21 studies in Urinary Bladder Neoplasms by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University are open now, in 1 country. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Where they have run

Who these studies take

Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Urinary Bladder Neoplasms by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, or all of them as a file.
02

Study summary

Bladder cancer is the most common malignant tumor of the urinary system. The presence or absence of muscle invasion in early bladder cancer is an independent prognostic factor. The involvement of muscle invasion affects the choice of surgical methods and treatment. Preoperatively, the precise assessment of bladder cancer staging has important practical value. A more accurate preoperative assessment of bladder cancer staging can reduce overtreatment and provide a favorable basis for clinicians to choose more reasonable and effective surgical methods. Clinically, there has been a longstanding desire to diagnose the staging of bladder cancer through a simple, convenient, effective, and non-invasive examination. As relevant research progresses, a multi-omics diagnostic model will be beneficial in improving diagnostic efficiency. This project aims to establish a multi-omics artificial intelligence system based on deep learning and transfer learning to accurately diagnose the staging of bladder cancer and predict the efficacy of neoadjuvant chemotherapy. This system will assist in clinical treatment decision-making.

Read the detailed description

Research Content

  1. Establishment of Ultrasound and Magnetic Resonance Imaging-Pathology-Clinical Dataset: This project aims to include medical records diagnosed through ultrasound and magnetic resonance imaging. Combining results from cytopathology or tissue pathology, the project will collect ultrasound images of the bladder, magnetic resonance images of the bladder, pathology images, and clinically relevant follow-up data. Tumor tissue specimens will be collected for immunohistochemical fluorescence staining. Participants with indistinct imaging findings or those with other primary malignant tumors will be excluded. The goal is to establish an ultrasound and magnetic resonance imaging-pathology-clinical dataset.
  2. Establishment of an Artificial Intelligence System for Precise Diagnosis of Bladder Cancer Staging and Prognosis based on Ultrasound Imaging: Collecting clinical baseline information, surgical pathology, and ultrasound images of enrolled subjects. The ultrasound images will undergo homogenization processing. Utilizing algorithms based on U-Net, Transformer, and attention mechanisms for tissue segmentation and feature extraction, a deep learning model based on convolutional neural networks will be established for precise diagnosis of bladder cancer staging and prognosis:

    Construction of a mathematical model for staging bladder cancer using ultrasound contrast: Using convolutional neural networks for deep learning to build a mathematical model for staging bladder cancer. Developing an artificial intelligence diagnostic system for ultrasound contrast images based on deep learning and mathematical models to determine whether bladder cancer has muscle invasion.

    Construction of a mathematical model to discriminate prognosis features of bladder cancer using ultrasound imaging: Automatically delineating target areas and extracting ultrasound image features of bladder cancer lesions using new artificial intelligence technology - convolutional neural networks to build a model for evaluating the prognosis of bladder cancer lesions and achieving accurate prognosis diagnosis.

  3. Establishment of an Artificial Intelligence System for the Joint Diagnosis of Bladder Cancer and Staging based on Ultrasound and Magnetic Resonance Imaging with Pathology: Based on bladder ultrasound, magnetic resonance imaging, and pathology image data, the baseline information of study subjects will be digitized. Ultrasound images, magnetic resonance images, and pathology images will undergo homogenization processing. Utilizing algorithms based on U-Net, Transformer, and attention mechanisms for segmentation and feature extraction of bladder ultrasound images, magnetic resonance images, and pathology images, a deep learning model based on convolutional neural networks will be established for the precise diagnosis of bladder cancer staging and prognosis:

    Construction of a mathematical model for joint pathology-based staging of bladder cancer using ultrasound and magnetic resonance imaging: Using convolutional neural networks for deep learning to build a mathematical model for staging bladder cancer. Based on the mathematical model, continuously optimizing algorithms, developing multi-omics, multidimensional artificial intelligence diagnostic systems based on ultrasound images, magnetic resonance images, pathology images, and clinical features, achieving accurate diagnosis of bladder cancer staging and prognosis prediction models.

    Construction of a mathematical model to discriminate prognosis features of bladder cancer using joint ultrasound, magnetic resonance, and pathology: Automatically delineating target areas and extracting features of bladder cancer lesions using convolutional neural networks and new artificial intelligence technology. Building a mathematical model to evaluate the prognosis of bladder cancer lesions.

    After the completion of the multi-omics, multidimensional artificial intelligence precise prediction model, validate the reliability of the model in prospective observational cohort study data and implement an intelligent system to assist in improving the efficiency of doctor diagnosis.

  4. Establishment of an Artificial Intelligence System based on Dynamic Quantitative Immune Cell Maps using Ultrasound Imaging: Based on bladder ultrasound and pathological immunohistochemistry data, artificial intelligence algorithms will accurately determine the expression of immune cells through ultrasound images. Visualization of 2D spatial distribution heatmaps will be conducted to explore the intercorrelation features between ultrasound images and immune cells. Study subjects will be divided into training and validation cohorts. The baseline information of study subjects will be digitized. Ultrasound images will undergo homogenization processing. Utilizing algorithms based on U-Net, Transformer, attention mechanisms, and generative adversarial networks for tissue segmentation, feature extraction, and model establishment:

Construction of a mathematical model for quantitative immune cell maps using ultrasound images: Using new artificial intelligence technology - convolutional neural networks for deep learning to build a mathematical model for predicting the expression of immune cells. Developing an artificial intelligence diagnostic system for quantifying the microenvironment of ultrasound contrast images, determining the expression of immune cells in bladder cancer lesions.

The model will combine the immune cells with the 2D ultrasound image prediction heatmap, forming a visual 2D ultrasound image-immune cell heatmap. Exploring the spatial location of immune cells in ultrasound images. Using single-cell and spatial transcriptome sequencing methods to verify the accuracy of the spatial distribution of ultrasound image-quantified immune cells.

03

Conditions studied

  • Bladder Cancer
  • Staging
  • Deep Learning
  • Neoadjuvant Chemotherapy
  • Contrast Enhanced Ultrasound

Keywords

  • Bladder Cancer
  • Multi-omics
  • Staging
  • Deep Learning
  • Neoadjuvant Chemotherapy
  • Contrast Enhanced Ultrasound
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

480 patients who were diagnosed with bladder cancer based on postoperative pathology at Sun Yat-sen Memorial Hospital, Sun Yat-sen University will be included between January 2023 and December 2026.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ultrasound and other imaging examinations (CT, MR, etc.) suggest bladder masses and are suspicious for bladder cancer patients.
  2. The bladder is well filled, and no allergic reactions to ultrasound contrast agents are found.
  3. No surgery or radiotherapy/chemotherapy has been performed.
  4. Patients who meet the indications for surgical resection and are planned for surgical treatment, including one of the following:

    1. Clinical symptoms consistent with suspected bladder cancer (such as gross hematuria, etc.);
    2. Patients with confirmed primary or recurrent bladder cancer by cystoscopic ;
    3. Rapid urine cytology and urine cytology FISH testing suggest .

Exclusion criteria

Exclusion Criteria:

  1. Individuals unable to tolerate surgery;
  2. Individuals allergic to ultrasound contrast agents, unable to undergo ultrasound contrast examination;
  3. Unsuccessful preoperative ultrasound contrast examination or non-compliant patients;
  4. Postoperative pathology does not indicate bladder cancer;
  5. Patients who have undergone chemotherapy or radiation therapy.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
480 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • Training Group

    Approximately 300 patients, which are used for the training dataset.

    Diagnostic Test: Risk Stratification

  • Internal Validation Group

    Approximately 100 patients, which are used for internal validation to assess the accuracy of the model.

    Diagnostic Test: Risk Stratification

  • External Validation Group

    Approximately 100 patients,which are used for external validation to assess the accuracy of the model.

    Diagnostic Test: Risk Stratification

Interventions

  • Diagnostic testRisk Stratification

    Risk Stratification for Assessing Muscle Infiltration in Bladder Cancer.

06

What researchers measure

Primary outcomes

  1. Detection of Muscle Invasion in Bladder Cancer

    To evaluate the preoperative staging of bladder cancer,whether it is non-muscle invasive bladder cancer (NMIBC) or muscle invasive bladder cancers (MIBC)

    Time frame: Perform contrast-enhanced ultrasound (CEUS) examination within 2 weeks before the procedure.

Secondary outcomes

  1. Evaluate the Diagnostic Performance of Deep Learning and Transfer Learning in Preoperative Prediction of Muscle-Invasive Status in Bladder Cancer

    The diagnostic performance of the Deep Learning and Transfer Learning Model was primarily evaluated using the statistical metrics of AUC (Area Under the ROC Curve), sensitivity, specificity, accuracy, negative predictive value (NPV), and positive predictive value (PPV).

    Time frame: The patient should return for follow-up at 3 months postoperatively

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4. PubMed 33538338 ↗
  • Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. Eur Urol. 2017 Jan;71(1):96-108. doi: 10.1016/j.eururo.2016.06.010. Epub 2016 Jun 28. PubMed 27370177 ↗
  • Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. Eur Urol. 2016 Jul;70(1):106-119. doi: 10.1016/j.eururo.2016.02.028. Epub 2016 Mar 17. PubMed 26996659 ↗
  • Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chang S, Downs TM, Efstathiou JA, Friedlander T, Greenberg RE, Guru KA, Guzzo T, Herr HW, Hoffman-Censits J, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Preston MA, Sexton WJ, Siefker-Radtke AO, Tward J, Wright JL, Gurski LA, Johnson-Chilla A. Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020 Mar;18(3):329-354. doi: 10.6004/jnccn.2020.0011. PubMed 32135513 ↗
  • Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, deVere White RW, Sarosdy MF, Wood DP Jr, Raghavan D, Crawford ED. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003 Aug 28;349(9):859-66. doi: 10.1056/NEJMoa022148. PubMed 12944571 ↗
  • Yin M, Joshi M, Meijer RP, Glantz M, Holder S, Harvey HA, Kaag M, Fransen van de Putte EE, Horenblas S, Drabick JJ. Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis. Oncologist. 2016 Jun;21(6):708-15. doi: 10.1634/theoncologist.2015-0440. Epub 2016 Apr 6. PubMed 27053504 ↗
  • Winquist E, Kirchner TS, Segal R, Chin J, Lukka H; Genitourinary Cancer Disease Site Group, Cancer Care Ontario Program in Evidence-based Care Practice Guidelines Initiative. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol. 2004 Feb;171(2 Pt 1):561-9. doi: 10.1097/01.ju.0000090967.08622.33. PubMed 14713760 ↗
  • Seiler R, Ashab HAD, Erho N, van Rhijn BWG, Winters B, Douglas J, Van Kessel KE, Fransen van de Putte EE, Sommerlad M, Wang NQ, Choeurng V, Gibb EA, Palmer-Aronsten B, Lam LL, Buerki C, Davicioni E, Sjodahl G, Kardos J, Hoadley KA, Lerner SP, McConkey DJ, Choi W, Kim WY, Kiss B, Thalmann GN, Todenhofer T, Crabb SJ, North S, Zwarthoff EC, Boormans JL, Wright J, Dall'Era M, van der Heijden MS, Black PC. Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy. Eur Urol. 2017 Oct;72(4):544-554. doi: 10.1016/j.eururo.2017.03.030. Epub 2017 Apr 5. PubMed 28390739 ↗
  • Makboul M, Farghaly S, Abdelkawi IF. Multiparametric MRI in differentiation between muscle invasive and non-muscle invasive urinary bladder cancer with vesical imaging reporting and data system (VI-RADS) application. Br J Radiol. 2019 Dec;92(1104):20190401. doi: 10.1259/bjr.20190401. Epub 2019 Oct 8. PubMed 31573328 ↗
  • Sidhu PS, Cantisani V, Dietrich CF, Gilja OH, Saftoiu A, Bartels E, Bertolotto M, Calliada F, Clevert DA, Cosgrove D, Deganello A, D'Onofrio M, Drudi FM, Freeman S, Harvey C, Jenssen C, Jung EM, Klauser AS, Lassau N, Meloni MF, Leen E, Nicolau C, Nolsoe C, Piscaglia F, Prada F, Prosch H, Radzina M, Savelli L, Weskott HP, Wijkstra H. The EFSUMB Guidelines and Recommendations for the Clinical Practice of Contrast-Enhanced Ultrasound (CEUS) in Non-Hepatic Applications: Update 2017 (Long Version). Ultraschall Med. 2018 Apr;39(2):e2-e44. doi: 10.1055/a-0586-1107. Epub 2018 Mar 6. PubMed 29510439 ↗
  • Hu FB. Metabolic profiling of diabetes: from black-box epidemiology to systems epidemiology. Clin Chem. 2011 Sep;57(9):1224-6. doi: 10.1373/clinchem.2011.167056. No abstract available. PubMed 21690202 ↗
  • Ou Q, Yu Y, Li A, Chen J, Yu T, Xu X, Xie X, Chen Y, Lin D, Zeng Q, Zhang Y, Tang X, Yao H, Luo B. Association of survival and genomic mutation signature with immunotherapy in patients with hepatocellular carcinoma. Ann Transl Med. 2020 Mar;8(5):230. doi: 10.21037/atm.2020.01.32. PubMed 32309377 ↗
  • Yu Y, Zeng D, Ou Q, Liu S, Li A, Chen Y, Lin D, Gao Q, Zhou H, Liao W, Yao H. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis. JAMA Netw Open. 2019 Jul 3;2(7):e196879. doi: 10.1001/jamanetworkopen.2019.6879. PubMed 31290993 ↗

Individual participant data

Plan to share: Yes

Supporting information: Statistical analysis plan, Analytic code

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Dec 2026, 35 months after the start.

Of 168 non-industry observational studies under Urinary Bladder Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 30. This study's planned 35 months is below that.

Counting every sponsor, half of 203 studies reached it within 58 months; a quarter within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2024
First posted
Jul 3, 2025
StartActual
Jan 1, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jul 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07051083
Responsible party
Qiyun Ou (Dr., Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University) — Principal investigator
First posted
Jul 3, 2025
Start date
Jan 1, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jul 3, 2025

Study contacts

Qiyun Ou, Dr.
Contact
ouqy5@mail.sysu.edu.cn
(86)020-34071020
Qiyun Ou, Dr.
principal investigator · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion